Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-2029 in advanced solid tumors and DLBCL
NCT03543813Phase 2Completed
- Sponsor
- CytomX
- Start
- Jun 2018
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 2, open-label trial of CX-2029 in solid tumor, diffuse large B-cell lymphoma (DLBCL), head and neck squamous cell carcinoma (HNSCC) and 2 more (3 arms), sponsored by CytomX. Primary endpoint: Dose-Limiting Toxicity at 21 days. Started Jun 2018; status: completed.
02
Drugs
CX-2029
03
Conditions
solid tumordiffuse large B-cell lymphoma (DLBCL)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)esophageal cancer
Beyond the preview
Go deeper on NCT03543813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03543813.